Abstracts tagged "certolizumab pegol"

Abstract Number: 1516 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
M. Victoria Hernández¹, Marina Mesquida¹, Victor Llorens², Maite Sainz de la Maza², Ricardo Blanco³, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Ana Urruticoechea-Arana⁷, Juan Ramon De Dios⁸, Pilar Ahijado-Guzman⁹, Enrique Judez¹⁰, Patricia Tejón¹¹, M Soledad Peña¹², Francisca Sivera¹³, Alfredo Adan¹ and Raimon Sanmarti¹⁴, ¹Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla., Santander, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Ophthalmology Department. Hospital Donostia, San Sebastian, Spain, ⁷Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁸Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁹Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ¹⁰Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹¹Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophtalmology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹³Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ¹⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis…
Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Rosa Expósito¹, Carlos M Gonzalez², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷ and Manuel Fernández⁸, ¹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain
Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…
Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data
Arantxa Conesa¹, Manuel Fernández², Rosa Expósito³, Jose Campos⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, Paula Rubio-Muñoz⁷, Pilar Ahijado-Guzman⁸ and Carlos M Gonzalez⁹, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Hospital Universitario de Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ⁴Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ⁹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
Abstract Number: 1519 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study
Carlos M Gonzalez¹, Rosa Expósito², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷, Manuel Fernández⁸ and Mercedes Morcillo⁹, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain, ⁹Rheumatology, Hospital El Escorial, San Lorenzo de el Escorial, Spain
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. RAPID-axSpA trial investigated the efficacy and…
Abstract Number: 1809 • 2017 ACR/ARHP Annual Meeting
Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Eliza Chakravarty¹, Frauke Förger², Bincy Abraham³, Ann Flynn⁴, Anna Moltó⁵, René-Marc Flipo⁶, Astrid van Tubergen⁷, Laura Shaughnessy⁸, Jeff Simpson⁸, Marie Teil⁹, Eric Helmer¹⁰, Maggie Wang⁸ and Xavier Mariette¹¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ³Houston Methodist Hospital, Houston, TX, ⁴University of Utah, Salt Lake City, UT, ⁵Hôpital Cochin, AP-HP, Paris, France, ⁶Centre Hospitalier Régional Universitaire de Lille, Lille, France, ⁷Maastricht University Medical Center, Maastricht, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: There is a need for effective and safe treatment during pregnancy in women affected by chronic active inflammatory diseases such as rheumatoid arthritis. Adequate…
Abstract Number: 594 • 2016 ACR/ARHP Annual Meeting
Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Clifton Bingham III¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Brenda VanLunen⁸, Oana Purcaru⁹ and Vivian P. Bykerk¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²University of Leeds, Leeds, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of physical function, work disability, and decreased quality of life. Early treatment with certolizumab pegol (CZP) in…
Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Hermine I. Brunner¹, Nicolino Ruperto², Vladimir Keltsev³, Ekaterina Alexeeva⁴, Carlos Abud-Mendoza⁵, Heinrike Schmeling⁶, María del Rocío Maldonado-Velázquez⁷, Nadina Rubio-Pérez⁸, Marina Stanislav⁹, Vyacheslav Chasnyk¹⁰, Diane Brown¹¹, Michael Henrickson¹, Daniel Kingsbury¹², C. Egla Rabinovich¹³, Andrew Zeft¹⁴, Earl Silverman¹⁵, Maggie Wang¹⁶, Philippa Charlton¹⁶, Rocio Lledo-Garcia¹⁷, Laura Shaughnessy¹⁶, Daniel J. Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Gaslini, Genoa, Italy, ³Togliatti City Clinical Hospital №5, Togliatti, Russian Federation, ⁴Children's Health of RAMS and IM Sechenov First Moscow State Medical University, Moscow, Russian Federation, ⁵Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁶Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁷Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁸Universidad Autónoma de Nuevo León, Nuevo León, Mexico, ⁹Research Rheumatology Institute V.A. Nassonova, Moscow, Russia, ¹⁰St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ¹¹Division of Rheumatology, Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA, ¹²Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹³Duke University Medical Center, Durham, NC, ¹⁴Cleveland Clinic, Pediatric Rheumatology, Cleveland, OH, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶UCB Pharma, Raleigh, NC, ¹⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…
Abstract Number: 1042 • 2016 ACR/ARHP Annual Meeting
Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Xenofon Baraliakos², Kay-Geert Hermann³, Robert Landewé⁴, Pedro Machado⁵, Walter Maksymowych⁶, Owen Davies⁷, Natasha de Peyrecave⁷, Bengt Hoepken⁸, Lars Bauer⁸, Tommi Nurminen⁸ and Jürgen Braun⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, Academic Medical Center, Amsterdam & Zuyderland Medical Center Heerlen, Amsterdam, Netherlands, ⁵Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ⁶Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: RAPID-axSpA (NCT01087762) was a long-term study in patients (pts) with axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP). This is the first report of…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1724 • 2016 ACR/ARHP Annual Meeting
The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Majed Khraishi¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Philip J. Mease⁵, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Tufts University School of Medicine, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA…
Abstract Number: 1731 • 2016 ACR/ARHP Annual Meeting
Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact…
Abstract Number: 2048 • 2016 ACR/ARHP Annual Meeting
Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
Megan E. B. Clowse¹, Frauke Förger², Caroline Hwang³, John Thorp⁴, Radboud J. E. M. Dolhain⁵, Astrid van Tubergen⁶, Laura Shaughnessy⁷, Jeff Simpson⁸, Marie Teil⁹, Nathalie Toublanc¹⁰, Maggie Wang⁸ and Thomas W. Hale¹¹, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Keck Hospital of USC, Los Angeles, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Texas Tech University School of Medicine, Amarillo, TX
Background/Purpose: Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding.…
Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting
The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Leslie R. Harrold^1,2, Heather J. Litman¹, Katherine C. Saunders¹, Kimberly J. Dandreo¹, Bernice Gershenson², Jeffrey D. Greenberg^1,3, Robert Low⁴, Jeffrey Stark⁴, Robert Suruki⁴, Srihari Jaganathan⁴ and Mohamed Yassine⁴, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³NYU School of Medicine, New York, NY, ⁴UCB Pharma, Smyrna, GA
Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…
Abstract Number: 135 • 2016 ACR/ARHP Annual Meeting
The 8-Joint Ultrasound Score Is a Useful Marker for Monitoring Therapeutic Response in Rheumatoid Arthritis
Ryusuke Yoshimi¹, Yukihiro Toyota¹, Naomi Tsuchida¹, Yumiko Sugiyama¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi², Maasa Tamura¹, Yukiko Asami¹, Yohei Kirino¹, Shigeru Ohno² and Hideaki Nakajima¹, ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ²Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Musculoskeletal ultrasonography (US) is one of the standard tools for the diagnosis and monitoring of rheumatoid arthritis (RA). Although we and other groups have…
Abstract Number: 441 • 2015 ACR/ARHP Annual Meeting
Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis
Takanori Fujimura, Takashi Fujimoto, Ryota Hara, Naoki Shimmyo, Yasunori Kobata, Akira Kido, Yasuhiro Akai and Yasuhito Tanaka, The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. It brings rapid improvement of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].